Ultragenyx Pharmaceutical RARE Royalty — Accounts Receivable Net

Similar metrics at other companies

HALORoyalties — Accounts receivable, net and contract assets

$298.12M+62.4%

TGTXProduct — Accounts Receivable Net

$27.2M+103%

SHAKLicensing receivables, net of allowance for doubtful accounts — Contract with customer, asset, net

$6.12M+7.4%

MCReceivables Net

$125.29M+34.2%

FNDReceivables, net

$104.33M+3.9%

WLYBAccounts Receivable Net Current

$244.16M+6.9%

Questions, answered.

What is Ultragenyx Pharmaceutical's royalty — accounts receivable net?

Ultragenyx Pharmaceutical (RARE) reported royalty — accounts receivable net of $39M in Q1 2026.

What does royalty — accounts receivable net mean?

This metric measures the outstanding balance of royalty payments owed to the company by licensees for products sold, net of any allowances for doubtful accounts. It represents the short-term credit extended to partners as part of the royalty collection cycle. Tracking this balance provides insight into the company's ability to efficiently convert royalty-based contractual earnings into actual cash flow.